Vanda Pharmaceuticals | VNDA - Actif À Court Terme





Actif À Court Terme Changement Date
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
Akebia Therapeutics USD 243.48M 9.47M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Anika Therapeutics USD 93.56M 9.8M 2026-03
Arrowhead Research USD 1.84B 665.36M 2026-03
AstraZeneca USD 29.61B 890M 2026-03
Bristol-Myers Squibb USD 27.21B 2.18B 2026-03
Eli Lilly USD 54.84B 794M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Heron Therapeutics USD 228.98M 9.08M 2026-03
Insmed USD 1.61B 181.04M 2026-03
J&J USD 59.17B 3.55B 2026-03
Lexicon Pharmaceuticals USD 186.03M 84.14M 2026-03
Ligand Pharmaceuticals USD 865.42M 33.14M 2026-03
Merck USD 35.02B 8.5B 2026-03
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Moderna USD 5.77B 774M 2026-03
Novartis USD 26.61B 3.85B 2026-03
Pfizer USD 42.82B 76M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Puma Biotechnology USD 143.58M 7M 2025-09
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Sanofi EUR 30.16B 789M 2026-03
Takeda JPY 3.09T 25.94B 2026-03
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12
Veracyte USD 522.17M 33.8M 2026-03